Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086359
Status:
COMPLETED
Last Update Posted:
2021-11-01
First Post:
2004-06-30
Brief Title:
Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
A Phase III Randomized Trial of the Safety and Antiretroviral Effects of ZidovudineLamivudineAbacavir Versus ZidovudineLamivudineLopinavirRitonavir in the Prevention of Perinatal Transmission of HIV
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Pregnant women infected with HIV who take anti-HIV medications during pregnancy lower the risk of passing HIV to their infants This study will compare how well two different combinations of anti-HIV medications control HIV in pregnancy and whether these combinations of drugs are effective in preventing HIV from being transmitted from a pregnant woman to her baby The two combinations are abacavirlamivudinezidovudine ABC3TCZDV and zidovudinelamivudine ZDV3TC plus lopinavirritonavir LPVRTV
Detailed Description:
Antiretroviral therapy ART in pregnancy has dramatically reduced the rates of perinatal HIV transmission Many pregnant women infected with HIV may not meet the criteria for treatment as set forth by the Department of Health and Human Services guidelines and would not be started on therapy if they were not pregnant Pregnant women are prescribed a variety of treatment regimens the optimum regimen for pregnant women who plan to discontinue therapy after delivery is unknown An optimum regimen would account for the need for maximum viral suppression minimal fetal toxicity and preservation of future therapeutic options for the mother This study will compare an all nucleoside reverse transcriptase inhibitor NRTI regimen of ABC3TCZDV with a standard protease inhibitor PI regimen of LPVRTV and 3TCZDV This study was initially designed for women who plan to take antiretrovirals only while pregnant and do not meet the criteria for treatment initiation if not pregnant However pregnant women who have taken ART for 180 days or less or have taken ZDV monotherapy for a total of 8 weeks or less prior to entering this study are eligible for Version 20 of this study
Women in this study will be randomly assigned to one of two groups Women in Group A will receive one pill ABC3TCZDV twice a day Women in Group B will receive one pill 3TCZDV and 4 pills LPVRTV twice a day Women will take their assigned medications until they go into labor Once in labor women will be given zidovudine through intravenous IV infusion they will stop taking oral zidovudine but will continue with their other medications After delivery all infants will be given zidovudine for six weeks
Women will have study visits every 2 weeks for the first 8 weeks of treatment and then every 4 weeks until Week 28 Depending on where a woman is in her pregnancy when she enrolls in the study she will also have study visits at Weeks 20 28 and 34 of her pregnancy At each visit women will have a medical interview a physical exam and an obstetrical exam blood and urine collection will occur at these visits Mothers will undergo a fetal ultrasound at Week 20 Adherence health status and behavior assessments will occur at selected visits prior to delivery
After delivery women will stop taking the study medications but will continue to have study visits at approximately 6 12 24 36 48 and 52 weeks after delivery Medical history and a physical exam will occur at all visits for mothers postpartum Blood collection will occur at every postpartum visit urine collection will occur 12 24 and 48 weeks postpartum health status and behavior assessments will occur at most visits postpartum Infants will have study visits at 2 16 and 24 weeks after birth A medical history physical exam and laboratory tests will be conducted at the infant study visits Women will also be asked to enroll their infants in PACTG 219C a long-term study that follows infants who are born to HIV infected mothers
Women in this study will be randomly assigned to one of two groups Women in Group A will receive one pill ABC3TCZDV twice a day Women in Group B will receive one pill 3TCZDV and 4 pills LPVRTV twice a day Women will take their assigned medications until they go into labor Once in labor women will be given zidovudine through intravenous IV infusion they will stop taking oral zidovudine but will continue with their other medications After delivery all infants will be given zidovudine for six weeks
Women will have study visits every 2 weeks for the first 8 weeks of treatment and then every 4 weeks until Week 28 Depending on where a woman is in her pregnancy when she enrolls in the study she will also have study visits at Weeks 20 28 and 34 of her pregnancy At each visit women will have a medical interview a physical exam and an obstetrical exam blood and urine collection will occur at these visits Mothers will undergo a fetal ultrasound at Week 20 Adherence health status and behavior assessments will occur at selected visits prior to delivery
After delivery women will stop taking the study medications but will continue to have study visits at approximately 6 12 24 36 48 and 52 weeks after delivery Medical history and a physical exam will occur at all visits for mothers postpartum Blood collection will occur at every postpartum visit urine collection will occur 12 24 and 48 weeks postpartum health status and behavior assessments will occur at most visits postpartum Infants will have study visits at 2 16 and 24 weeks after birth A medical history physical exam and laboratory tests will be conducted at the infant study visits Women will also be asked to enroll their infants in PACTG 219C a long-term study that follows infants who are born to HIV infected mothers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PACTG P1039 | Registry Identifier | DAIDS ES | None |
| 10046 | REGISTRY | None | None |